Abstract: This application claims a method for detecting biologically active substances, comprising the following steps a) providing a support carrying substances to be tested b) providing a suspension containing luminescent microorganisms, c) coating the support with the suspension of microorganisms, d) detecting the biologically active substances on the support by detecting the change in luminescence of the suspension of microorganisms, and e) stimulating the luminescence of the microorganisms before or during detection, and/or f) extending the period of luminescence of the microorganisms by employing substances for regulating and extending the period of luminescence of the microorganisms.

Abstract: The invention relates to a diffusion-controlling sensor layer for detecting the biological effect of substances consisting of a diffusion-controlling matrix and sensors suspended therein. The invention further comprises a method and an apparatus for the location-dependent detection of the biological effect of substances using the sensor layer according to the invention (“imaging” of the spatial distribution of biological activity). A further embodiment of the method according to the invention relates to the coupling of investigations of the biological activity of substances with chromatographic and electrophoretic separation techniques so that biologically active individual substances can be identified directly in mixtures. An additional embodiment of the method according to the invention comprises the direct combination of the detection of the effect via sensor layers with chromatographic and electrophoretic separation techniques which are in turn coupled to spectroscopic techniques.

Abstract: This application claims a method for detecting biologically active substances, comprising the following steps a) providing a support carrying substances to be tested b) providing a suspension containing luminescent microorganisms, c) coating the support with the suspension of microorganisms, d) detecting the biologically active substances on the support by detecting the change in luminescence of the suspension of microorganisms, and e) stimulating the luminescence of the microorganisms before or during detection, and/or f) extending the period of luminescence of the microorganisms by employing substances for regulating and extending the period of luminescence of the microorganisms.

Abstract: The invention claimed herein is a kit for detecting biologically active substances on a support, comprising the luminescent marine bacteria Vibria Fischeri in a form stabilized for transport and storage, one or more cultivation media or the individual components of cultivation media for the microorganism wherein the cultivation media contains 100 mg/l to 500 mg/l of aspartic acid, and optionally additives for extending the period of luminescence selected from N-acylhomoserine lactones, dipeptides, oligopeptides, or their biochemical precursors, and boron compounds.

Abstract: The present invention relates to orally administrable multiple-unit sustained-release dose forms having controlled agitation-independent release of active compound and processes for their production using a selected erodable hydrophilic polymer (HPC) and a limitation of the maximum size of the active compound-containing polymer particles to ≦3 mm.

Abstract: The invention relates to a method for detecting biologically active substances, comprising the steps

Abstract: The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.

Abstract: This invention relates to an orally administered osmotic drug release system that consists of a shell and a core containing a pharmaceutically active substance, as well as a process for its production. The invention relates further to an osmotic drug release system for use as a drug in human beings and animals, as well as the use of the osmotic drug release system in the production of a drug for the treatment and/or prevention of illnesses in human beings and animals.

Abstract: The mixture to be tested for toxic components is first separated into fractions by chromatography. The separated fractions are then contacted with luminescent microorganisms in the chromatographic system itself and the toxicity of the fractions is determined by measurement of the bioluminescence. The chromatographic separation may be carried out either by thin layer chromatography or by column liquid chromatography.

Abstract: In a process for deacidifying and improving the flavor of so called secondary extracts obtained in the production of instant coffees, the secondary extracts are pumped over alkaline molecular sieves and are therewith completely or partially liberated from acids and flavor-impeding organic compounds.

Abstract: The quality of Robusta coffee is increased by treating raw Robusta coffee beans whose water content has been increased to about 30% to 45% with steam at about 135.degree. C. to 140.degree. C. and at a pressure ranging from 3 bar to 4 bar approx. for 60 min to 120 min. This treatment particularly removes the substance responsible for the "earthy" and "musty" aroma note of Robusta coffee, namely the compound 2-methylisoborneol. After the treatment, the beans are processed and roasted in the customary way.